Genzyme General Announces Two-For-One Stock Split

Apr 25, 2001, 01:00 ET from Genzyme General

    CAMBRIDGE, Mass., April 25 /PRNewswire Interactive News Release/ --
 Genzyme Corp. announced today that its board of directors has approved a two-
 for-one split of Genzyme General (Nasdaq:   GENZ) common stock, subject to the
 approval by shareholders of an increase in the number of authorized shares of
 Genzyme common stock.
     At the company's annual shareholders meeting on May 31, 2001, shareholders
 will be asked to approve an amendment to the corporation's charter increasing
 the total number of authorized shares of Genzyme common stock from 390,000,000
 to 690,000,000 shares and increasing the number of such shares designated as
 Genzyme General stock from 200,000,000 to 500,000,000 shares.
     Assuming the amendment is approved, Genzyme will issue on June 1, 2001,
 one new share of Genzyme General common stock for each share of common stock
 held by Genzyme General shareholders of record as of May 24, 2001.  Securities
 convertible into Genzyme General common stock will also adjust to reflect this
 stock split.
     "This action underscores the strong sense of confidence we have in the
 future growth of Genzyme General," said Henri A. Termeer, chairman and chief
 executive officer of Genzyme Corp.
     Genzyme General develops and markets therapeutic products and diagnostic
 products and services.  Genzyme General has four therapeutic products on the
 market and a strong pipeline of therapeutic products in development focused
 primarily on the treatment of genetic diseases and other chronic, debilitating
 disorders with well-defined patient populations. Genzyme General is a division
 of the biotechnology company Genzyme Corporation.
     This press release contains forward-looking statements based on
 management's current expectations, including without limitation the
 performance of Genzyme General.  Actual results may materially differ due to
 numerous factors, including the actual results of Genzyme General's
 operations, the ability of Genzyme General to obtain approval and increase
 market acceptance for its products and services; the continued funding of
 collaborations by Genzyme and its partners; the ability to obtain, maintain
 and successfully enforce adequate patent coverage for Genzyme General's
 products and services; the ability to manufacture sufficient quantities of
 products for development and commercialization activities; the competitive
 environment in the market for Genzyme General's products and services; and the
 risks and uncertainties described in reports filed by Genzyme with the
 Securities and Exchange Commission under the Securities Exchange Act of 1934,
 as amended, including without limitation Exhibit 99.2 to Genzyme's 2000 Annual
 Report on Form 10-K. Genzyme General stock is a series of common stock of
 Genzyme Corporation. Therefore, holders of Genzyme General stock are subject
 to all of the risks and uncertainties described in the reports filed by
 Genzyme Corporation with the Securities and Exchange Commission.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X74033441
 
 

SOURCE Genzyme General
    CAMBRIDGE, Mass., April 25 /PRNewswire Interactive News Release/ --
 Genzyme Corp. announced today that its board of directors has approved a two-
 for-one split of Genzyme General (Nasdaq:   GENZ) common stock, subject to the
 approval by shareholders of an increase in the number of authorized shares of
 Genzyme common stock.
     At the company's annual shareholders meeting on May 31, 2001, shareholders
 will be asked to approve an amendment to the corporation's charter increasing
 the total number of authorized shares of Genzyme common stock from 390,000,000
 to 690,000,000 shares and increasing the number of such shares designated as
 Genzyme General stock from 200,000,000 to 500,000,000 shares.
     Assuming the amendment is approved, Genzyme will issue on June 1, 2001,
 one new share of Genzyme General common stock for each share of common stock
 held by Genzyme General shareholders of record as of May 24, 2001.  Securities
 convertible into Genzyme General common stock will also adjust to reflect this
 stock split.
     "This action underscores the strong sense of confidence we have in the
 future growth of Genzyme General," said Henri A. Termeer, chairman and chief
 executive officer of Genzyme Corp.
     Genzyme General develops and markets therapeutic products and diagnostic
 products and services.  Genzyme General has four therapeutic products on the
 market and a strong pipeline of therapeutic products in development focused
 primarily on the treatment of genetic diseases and other chronic, debilitating
 disorders with well-defined patient populations. Genzyme General is a division
 of the biotechnology company Genzyme Corporation.
     This press release contains forward-looking statements based on
 management's current expectations, including without limitation the
 performance of Genzyme General.  Actual results may materially differ due to
 numerous factors, including the actual results of Genzyme General's
 operations, the ability of Genzyme General to obtain approval and increase
 market acceptance for its products and services; the continued funding of
 collaborations by Genzyme and its partners; the ability to obtain, maintain
 and successfully enforce adequate patent coverage for Genzyme General's
 products and services; the ability to manufacture sufficient quantities of
 products for development and commercialization activities; the competitive
 environment in the market for Genzyme General's products and services; and the
 risks and uncertainties described in reports filed by Genzyme with the
 Securities and Exchange Commission under the Securities Exchange Act of 1934,
 as amended, including without limitation Exhibit 99.2 to Genzyme's 2000 Annual
 Report on Form 10-K. Genzyme General stock is a series of common stock of
 Genzyme Corporation. Therefore, holders of Genzyme General stock are subject
 to all of the risks and uncertainties described in the reports filed by
 Genzyme Corporation with the Securities and Exchange Commission.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X74033441
 
 SOURCE  Genzyme General